Home / Deep Research / Oppositional Defiant Disorder

Oppositional Defiant Disorder

1. Disease Information

2026-04-24
Falcon MONDO:0000495 Model: Edison Scientific Literature 38 citations

1. Disease Information

1.1 Overview / concise definition

Oppositional Defiant Disorder (ODD) is a disruptive behavior disorder characterized by a persistent pattern of angry/irritable mood, argumentative/defiant behavior, and vindictiveness that causes distress or impairment. DSM-5-TR conceptualizes ODD symptoms across these three dimensions. (hawes2023oppositionaldefiantdisorder pages 1-6, hawes2023oppositionaldefiantdisorder pages 55-59)

A DSM-5–based diagnostic summary in the retrieved corpus describes ODD as “a pattern of angry/irritable mood, argumentative/defiant behaviour, or vindictiveness lasting ≥ 6 months” with a minimum number of symptoms and impairment, and severity specified by the number of settings affected. (hawes2023oppositionaldefiantdisorder pages 55-59)

1.2 Key identifiers / classification (available evidence)

Important limitation: The retrieved full texts did not provide explicit ICD-10/ICD-11 alphanumeric code strings, MeSH IDs, or MONDO IDs; the below reflects classification placement and specifier content only.

  • DSM-5-TR: ODD is defined by symptom criteria and a severity specifier based on number of settings. (hawes2023oppositionaldefiantdisorder pages 16-19, hawes2023oppositionaldefiantdisorder pages 55-59)
  • ICD-10 vs ICD-11 placement (as stated in retrieved text): one source states that in ICD-10, ODD was classified as a subtype of Conduct Disorder, whereas in ICD-11 it is classified within a “Disruptive behaviour or dissocial disorder” grouping (with Conduct Disorder also included). (balia2020…behaviourin pages 26-29)
  • ICD-11 specifiers highlighted in the 2023 Primer: ‘with limited prosocial emotions (LPE)’, ‘with chronic irritability-anger’, and ‘without chronic irritability-anger’. (hawes2023oppositionaldefiantdisorder pages 19-22)

1.3 Synonyms / alternative names

Common clinical phrasing includes “oppositional-defiant behavior” and “oppositional defiant symptoms.” (NCT06410495 chunk 1, NCT06194994 chunk 1)

1.4 Evidence source types

This report is based on aggregated disease-level resources (review/primer, meta-analysis), plus human clinical trials/cohorts, and molecular/physiology studies. (hawes2023oppositionaldefiantdisorder pages 1-6, boldrini2023systematicreviewand pages 9-12, ezpeleta2019firstincidenceage pages 1-2, barker2018amethylomewideassociation pages 1-2)

2. Etiology

2.1 Disease causal factors (multifactorial)

Current synthesis supports ODD as a multifactorial disorder arising from interactions between genetic liability and environmental contexts, with social-relationship mechanisms contributing to symptom maintenance. (hawes2023oppositionaldefiantdisorder pages 1-6)

2.2 Risk factors (genetic and environmental)

Genetic risk (heritability; polygenic architecture)

Twin/family evidence summarized in the 2023 Nature Reviews Disease Primers article indicates moderate-to-high heritability for ODD, with reported ranges 0.34–0.73, and substantial non-shared environmental influence. (hawes2023oppositionaldefiantdisorder pages 6-9)

In a GWAS/candidate-gene study of ODD symptom dimensions in an ADHD clinical sample, the background states that ODD heritability has been estimated around 0.60, while molecular findings were limited (no genome-wide significant hits in that study). (aebi2016gene‐setandmultivariate pages 1-2)

Environmental / psychosocial risk

A longitudinal cohort study (ages 3–9) identified risk factors for a first ODD episode including negative affectivity, difficulties in inhibitory and emotional control, punitive parenting, and maternal internalising problems, among others. (ezpeleta2019firstincidenceage pages 1-2)

2.3 Protective factors

Explicit protective factors were not enumerated as such in the retrieved excerpts. Indirectly, the treatment literature and longitudinal work imply that early identification, supportive parenting practices, and evidence-based interventions can improve outcomes and may function as protective influences at the population level. (hawes2023oppositionaldefiantdisorder pages 33-36, ezpeleta2019firstincidenceage pages 1-2)

2.4 Gene–environment and developmental embedding (epigenetic evidence)

A methylome-wide association study using DNA methylation at birth and trajectories of ODD behaviors (ages 7–13) reported that methylation signatures associated with ODD/headstrong trajectories were linked to prenatal risk exposures (e.g., maternal anxiety; cigarette smoking) and were partly genetically influenced, consistent with developmental embedding of exposures. The abstract states: “DNA methylation associated with prenatal risk exposures of maternal anxiety (headstrong) and cigarette smoking (ODD and headstrong).” (barker2018amethylomewideassociation pages 1-2)

3. Phenotypes

3.1 Core clinical phenotype domains

ODD symptom dimensions (DSM-5-TR framing) include: - Angry/irritable mood - Argumentative/defiant behavior - Vindictiveness (hawes2023oppositionaldefiantdisorder pages 1-6, hawes2023oppositionaldefiantdisorder pages 55-59)

DSM-5-TR criteria summarized in the 2023 Primer include 8 symptom items (e.g., temper loss, touchy/easily annoyed, angry/resentful; argues with authority figures; defies/refuses; deliberately annoys; blames others; spiteful/vindictive), with duration ≥6 months and impairment/distress requirements. (hawes2023oppositionaldefiantdisorder pages 55-59, hawes2023oppositionaldefiantdisorder pages 16-19)

3.2 Age of onset, progression, and frequency

3.3 Heterogeneity and specifiers/subtypes

3.4 Quality-of-life and functioning impacts

ODD can persist into adolescence/adulthood and is associated with adverse outcomes across health, education, employment, and relationships, with heterogeneity (outcomes not inevitable if symptoms desist). (hawes2023oppositionaldefiantdisorder pages 33-36)

A symptom-level impairment study in a clinical ADHD/DBD cohort reported that individual ODD symptoms differ in functional impact; for example, the ODD symptom “Argues with Adults” contributed strongly to explained variance in global functional impairment linked to disruptive symptoms. (hawes2023oppositionaldefiantdisorder pages 6-9)

3.5 Suggested HPO terms (examples; ontology suggestions)

Note: These are suggested mappings based on the described clinical features; direct HPO database extraction was not performed in-tool. - Irritable mood / anger: HP:0000737 (Irritability) (suggested) - Temper outbursts: HP:0000719 (Aggressive behavior) (suggested) - Defiant/argumentative behavior: HP:0031936 (Oppositional behavior) (suggested; term availability may vary) - Vindictiveness/spitefulness: map to behavioral abnormality terms under Abnormality of behavior (HP:0000708) (suggested) - Executive dysfunction: HP:0031510 (Executive dysfunction) (suggested)

4. Genetic/Molecular Information

4.1 Causal genes

No single causal gene is established for ODD in the retrieved evidence; ODD is best supported as polygenic/multifactorial with shared liability across externalizing phenotypes. (hawes2023oppositionaldefiantdisorder pages 6-9)

4.2 Molecular genetic findings (primary literature)

A GWAS/candidate-gene study of ODD subdimensions in ADHD evaluated polymorphisms in dopaminergic/serotonergic/oxytocin pathways (including DRD4 exon3 VNTR, 5-HTTLPR, OXTR SNPs) and performed multivariate GWAS, but reported no genome-wide significant loci; top-ranked genes formed an interaction landscape centered on beta-catenin signaling and neurite outgrowth. (aebi2016gene‐setandmultivariate pages 1-2)

A broader GWAS in ADHD with disruptive behavior disorders (including ODD/CD) identified genome-wide significant loci (e.g., rs7118422; OR 1.17), and found higher SNP-heritability for ADHD+DBDs vs ADHD alone (0.34 vs 0.20), with strong genetic correlations with aggression and antisocial behavior (rg ~0.81–0.82). (aebi2016gene‐setandmultivariate pages 1-2)

4.3 Epigenetic information

The methylome-wide study (birth methylation → ODD trajectories) supports epigenetic correlates and prenatal exposure associations (maternal anxiety; cigarette smoking). (barker2018amethylomewideassociation pages 1-2)

4.4 Somatic vs germline; allele frequencies; ClinVar-type variant annotations

Not available / not applicable in retrieved evidence.

5. Environmental Information

The retrieved evidence emphasizes psychosocial and family-system factors rather than toxins/occupational exposures.

6. Mechanism / Pathophysiology

6.1 Systems-level mechanistic models

A key mechanistic account highlights coercive parent–child cycles maintained by social learning and reinforcement, potentially evolving into maladaptive relational strategies and sustaining oppositional behavior. (hawes2023oppositionaldefiantdisorder pages 55-59)

6.2 Neurocognitive mechanisms

ODD has been linked to deficits in reinforcement learning, emotion processing, and social cognition, including impaired learning from punishment and difficulties recognizing negative facial expressions (especially anger), and executive function/self-regulation deficits that may persist even without ADHD comorbidity. (hawes2023oppositionaldefiantdisorder pages 12-16)

A neuropsychological case-control study found that visual working memory and inhibitory control were impaired in ODD and CD groups vs controls, and that anger recognition was impaired in ODD; deficits were not explained by ADHD/internalizing comorbidity. (hawes2023oppositionaldefiantdisorder pages 16-19)

6.3 Neuroimaging correlates

The 2023 Primer summarizes structural MRI findings including reduced volumes in orbitofrontal and ventromedial prefrontal regions (some patterns suggested as more ODD-specific) and functional hypo-responsivity across amygdala/insula/OFC/ACC/striatal and other regions involved in emotion recognition/regulation, error processing, and reward learning. (hawes2023oppositionaldefiantdisorder pages 55-59)

6.4 Stress physiology / autonomic function (biomarker-adjacent)

The 2023 Primer notes associations between ODD and lower basal cortisol and blunted cortisol responses to psychological stress, and reports that cortisol hyporeactivity predicts weaker response to parent management training in ODD. (hawes2023oppositionaldefiantdisorder pages 12-16)

6.5 Suggested GO biological process terms (examples; suggestions)

  • Emotion regulation: GO:0019220 (regulation of nervous system process) / GO:0032091 (negative regulation of protein binding) not specific; more appropriate is GO:0019220-like; specific emotion terms are limited in GO; consider GO:0050890 (cognition) and GO:0007610 (behavior) (suggested)
  • Reward learning / reinforcement: GO:0007611 (learning or memory) (suggested)
  • Stress response: GO:0006950 (response to stress) (suggested)

6.6 Suggested Cell Ontology (CL) terms (examples; suggestions)

Mechanisms implicate corticolimbic circuits; cell types are not directly assayed in retrieved evidence. Candidate CL terms for annotation (hypothesis-level): - CL:0000540 (neuron) - CL:0000127 (astrocyte) - CL:0000548 (animal cell) (general)

7. Anatomical Structures Affected

ODD is primarily a neurobehavioral disorder with correlates in brain systems for emotion regulation, reward/punishment learning, and executive control.

Neuroimaging synthesis implicates: - Amygdala, anterior insula, orbitofrontal cortex, anterior cingulate cortex, striatum, and ventromedial prefrontal regions, among others. (hawes2023oppositionaldefiantdisorder pages 55-59, hawes2023oppositionaldefiantdisorder pages 16-19)

Suggested UBERON terms (examples; suggestions): - UBERON:0000955 (brain) - UBERON:0001873 (amygdala) - UBERON:0000451 (prefrontal cortex) - UBERON:0001882 (striatum)

8. Temporal Development

9. Inheritance and Population

9.1 Epidemiology

Representative-sample point prevalence estimates cluster around ~3–5% (meta-analyses summarized in the 2023 Primer: ~3.3% ages 5–18; ~3.9% ages 1–7). Clinical and juvenile-justice samples show substantially higher rates (clinical 28–65%; juvenile justice ~43%). (hawes2023oppositionaldefiantdisorder pages 6-9)

A cumulative lifetime prevalence estimate of ~10.2% is mentioned in the 2023 Primer (noted as variable across samples). (hawes2023oppositionaldefiantdisorder pages 6-9)

9.2 Sex ratio

A modest male predominance is reported in childhood (~1.6–1.7:1), diminishing by adolescence; adult sex differences may be absent in some samples. (hawes2023oppositionaldefiantdisorder pages 6-9)

9.3 Genetic architecture

ODD shows moderate-to-high heritability and shared genetic liability with externalizing and internalizing phenotypes, loading on a higher-order externalizing genetic factor. (hawes2023oppositionaldefiantdisorder pages 6-9)

10. Diagnostics

10.1 Clinical criteria and assessment

DSM-5-TR criteria require ≥4 symptoms (of 8), duration ≥6 months, distress/impairment, and frequency thresholds depending on age (<5 years: most days; ≥5 years: at least once per week). (hawes2023oppositionaldefiantdisorder pages 16-19)

10.2 Specifiers and differential diagnosis considerations

ICD-11 introduces specifiers (LPE; chronic irritability-anger) that reflect heterogeneity and overlap with callous–unemotional traits and chronic irritability phenotypes. (hawes2023oppositionaldefiantdisorder pages 19-22)

The 2023 Primer notes that DSM-IV previously excluded ODD when CD was present, and DSM-5 removed that restriction, affecting prevalence estimation and diagnostic conventions. (hawes2023oppositionaldefiantdisorder pages 6-9)

10.3 Screening instruments and workflow (real-world)

The 2023 Primer describes a stepped approach: parent/teacher rating scales for screening, followed by more intensive clinical interviews/observations for those screening positive; obtaining multi-informant data is important because cross-setting symptoms indicate severity. Examples include ASEBA and BASC-3 (normed but not DSM-item aligned), SDQ (brief), and DSM-aligned scales like the DBD Rating Scale; parent-rated DBD showed positive predictive power >0.90 for structured interview diagnoses in pediatric samples cited in the Primer. (hawes2023oppositionaldefiantdisorder pages 19-22)

Suggested MAXO terms: - Screening for behavioral disorder: MAXO:0000506 (screening procedure) (suggested) - Structured diagnostic interview: MAXO:0000471 (psychiatric evaluation) (suggested)

11. Outcome / Prognosis

ODD is associated with broad impairment and can persist into adulthood, but outcomes are heterogeneous; desistence is associated with better prognosis. (hawes2023oppositionaldefiantdisorder pages 33-36)

A Spanish cohort analysis reported that early onset was associated with markedly higher depression risk; one excerpt notes increased risk of depression “by 5.76” versus children without ODD (as reported in the paper excerpt). (ezpeleta2019firstincidenceage pages 6-7)

Comorbidity profiles may predict worse functioning and poorer long-term treatment outcomes; in a clinical sample, the “Moderate Anxiety/High Conduct Problems” subgroup had worse executive functioning/emotional self-control and worse long-term psychosocial treatment outcomes. (halldorsdottir2023cooccurringconductproblems pages 1-2)

12. Treatment

12.1 Psychosocial interventions (first-line evidence base)

Parenting interventions grounded in social learning principles have the strongest empirical support across childhood and adolescence, with developmental staging enabling increased child participation and teacher/individual components for older youth. (hawes2023oppositionaldefiantdisorder pages 55-59)

A 2-year follow-up RCT comparing PMT vs PMT + group CBT (Coping Power Program) found long-term effectiveness of both arms for reduced disruptive behavior problems and harsh parenting and increased emotion regulation/social communication; combined treatment did not provide broad long-term benefits beyond PMT except earlier improvements in emotion regulation/social communication. (hawes2023oppositionaldefiantdisorder pages 1-6)

A 2024 RCT in Brazil comparing online vs face-to-face parent training (as add-ons to standard treatment) found: “Parent training was effective in reducing symptoms of ADHD (p = 0.030) and ODD (p = 0.026) irrespective of modality (p = 1.000).” (paiva2024parenttrainingfor pages 1-2)

A 2023 meta-analysis of psychosocial treatments for disruptive behavior disorders in adolescence synthesized RCTs across psychotherapy/training/counseling and delivery formats (group/family/individual/school-linked combined), supporting psychosocial treatment efficacy as a category while emphasizing methodological variation. (boldrini2023systematicreviewand pages 9-12)

Suggested MAXO terms: - Behavioral parent training / parent management training: MAXO:0000217 (behavior therapy) (suggested) - Cognitive behavioral therapy: MAXO:0000127 (cognitive behavioral therapy) (suggested) - Telehealth delivery of behavioral intervention: MAXO:0000753 (telemedicine) (suggested)

12.2 Pharmacotherapy

No ODD-specific pharmacotherapy standard was established in the retrieved evidence; medication trials largely target comorbid ADHD with ODD outcomes.

Examples from ClinicalTrials.gov: - Atomoxetine trial in ADHD + ODD (COMPLETED; N=181; primary endpoint SNAP-IV Revised ODD subscale at 9 weeks). (NCT00406354 chunk 1) - Clonidine extended-release oral suspension (Onyda XR) Phase IV trial planned for ADHD + ODD with ODD outcomes including Conners 4 ODD scale. (NCT07044609 chunk 1, NCT07044609 chunk 2)

13. Prevention

The 2023 Primer emphasizes early- to middle-childhood as the key window when interventions may be most effective and economical and could prevent chronic antisocial trajectories. (hawes2023oppositionaldefiantdisorder pages 36-39, hawes2023oppositionaldefiantdisorder pages 33-36)

Prevention/implementation barriers include limited infrastructure in underserved areas, parental mental health/household adversity affecting engagement, and low mental health literacy (ODD dismissed as “bad behaviour”). (hawes2023oppositionaldefiantdisorder pages 36-39)

Suggested MAXO terms: - Early intervention: MAXO:0000747 (early intervention) (suggested) - Parenting support/education: MAXO:0000208 (patient education) (suggested)

14. Other Species / Natural Disease

No veterinary/natural disease analogs with explicit taxonomy identifiers were found in the retrieved evidence set; therefore, this section is not available from current sources.

15. Model Organisms

No validated model-organism systems specific to ODD were identified in the retrieved corpus; mechanistic evidence is largely human neuroimaging/psychophysiology and epidemiologic genetics rather than animal models. (hawes2023oppositionaldefiantdisorder pages 12-16, hawes2023oppositionaldefiantdisorder pages 55-59)

2023–2024 Recent Developments (high priority)

Key recent advances in 2023–2024 sources include: 1. High-authority synthesis of ODD across diagnosis, epidemiology, mechanisms, and implementation in Nature Reviews Disease Primers (2023), consolidating prevalence (~3–5%), comorbidity rates, heritability estimates, and identifying key mechanistic hypotheses (emotion-regulation circuitry; punishment sensitivity) and implementation gaps. (hawes2023oppositionaldefiantdisorder pages 1-6, hawes2023oppositionaldefiantdisorder pages 6-9, hawes2023oppositionaldefiantdisorder pages 33-36) 2. Digital/online parent training implementation evidence (2024 RCT) demonstrating online PT can reduce ODD symptoms comparably to face-to-face delivery, supporting scalable service delivery in low-resource contexts. (paiva2024parenttrainingfor pages 1-2) 3. Phenotype stratification for prognosis/treatment response in treatment-seeking youth, where co-occurring conduct problems and anxiety define subgroups with differential executive/emotion-control deficits and outcomes. (halldorsdottir2023cooccurringconductproblems pages 1-2) 4. New/active trials focusing on moderators and comorbid targets, including an RCT explicitly testing emotion regulation as a treatment moderator (NCT06194994) and digital dyadic sleep/insomnia intervention for youth with ODD (NCT06410495). (NCT06194994 chunk 1, NCT06410495 chunk 1)

Evidence-synthesis Table (key sources)

Table (click to expand)
Source (first author, year) Type (review/RCT/cohort/epigenetics/GWAS/registry) Population Key findings/statistics Mechanism highlights PMID URL Publication date/month
Hawes, 2023 Review / Primer ODD across child/adolescent populations; synthesizes epidemiology, diagnosis, neurobiology, treatment Population prevalence ~3–5%; lifetime prevalence estimate ~10.2%; male predominance in childhood ~1.6–1.7:1; common co-occurrence: ADHD 28.9%, separation anxiety 20.3%, generalized anxiety 14.9%, depressive disorder 13.9%, CD 11.5%; heritability 0.34–0.73; onset typically before age 8; parenting interventions have strongest support, with brief early-childhood parenting interventions showing large effects and broader disruptive-behavior interventions moderate effects (hawes2023oppositionaldefiantdisorder pages 1-6, hawes2023oppositionaldefiantdisorder pages 6-9, hawes2023oppositionaldefiantdisorder pages 55-59, hawes2023oppositionaldefiantdisorder pages 33-36) ODD conceptualized in dimensions (angry/irritable, argumentative/defiant, vindictive); coercive parent–child cycles; reduced amygdala/insula/OFC/ACC/striatal responses; altered reward/punishment processing; cortisol hypo-reactivity and autonomic hypoarousal support emotion-regulation and social-cognitive dysfunction models (hawes2023oppositionaldefiantdisorder pages 16-19, hawes2023oppositionaldefiantdisorder pages 12-16, hawes2023oppositionaldefiantdisorder pages 19-22) Not in text https://doi.org/10.1038/s41572-023-00441-6 Jun 2023
Ezpeleta, 2019 Cohort Spanish general-population children followed ages 3–9 Probability of onset increased at age 4 (2.7%) and 5 (4.4%), decreased to age 7 (1.9%), rose again by age 9 (3.6%); cumulative risk of new ODD cases up to age 9 was 21.9%; pooled prevalence cited as 3.6%; early onset linked to higher depression comorbidity, later onset to greater impairment/symptom burden (ezpeleta2019firstincidenceage pages 1-2) Risk factors for first episode included subthreshold ODD, high irritability/headstrong symptoms, ADHD and other comorbidity, negative affectivity, poor inhibitory/emotional control, punitive parenting, maternal internalizing problems (ezpeleta2019firstincidenceage pages 1-2) Not in text https://doi.org/10.1136/bmjopen-2018-022493 Mar 2019
Helander, 2023 RCT follow-up Children with ODD in randomized trial of parent management training (PMT) vs PMT + Coping Power Program Two-year follow-up: both PMT alone and PMT+CBT reduced disruptive behavior problems and harsh parenting and improved emotion regulation/social communication; combination did not show significant long-term superiority over PMT alone overall (helander2023parentmanagementtraining pages 5-7) Suggests durable benefit of parenting-focused intervention; emotion-regulation and social-communication skills are modifiable treatment targets (helander2023parentmanagementtraining pages 5-7) Not in text https://doi.org/10.1007/s10578-021-01306-3 Jan 2023
Paiva, 2024 RCT Families of children with ADHD and disruptive behavior/ODD symptoms in Brazil; standard treatment vs online PT vs face-to-face PT ODD comorbidity in ADHD noted as reaching 50% in background; parent training reduced ADHD symptoms (p=0.030) and ODD symptoms (p=0.026) irrespective of online vs face-to-face modality (modality p=1.000); improved physical quality-of-life domains for children (p=0.009) and parents (p=0.050) (paiva2024parenttrainingfor pages 1-2) Supports scalable digital/online parent-training implementation where access is limited; family environment emphasized as prognostically important (paiva2024parenttrainingfor pages 1-2) Not in text https://doi.org/10.3389/fpsyg.2024.1293244 Feb 2024
Boldrini, 2023 Systematic review / meta-analysis 17 RCTs, 1,954 adolescents (61% male), mean age 14.09 years, with ODD/CD/externalizing symptoms Included psychotherapy, training, counseling, combined psychosocial interventions; designed to meta-analyze change in externalizing symptoms and acceptability across psychosocial treatments in adolescence (boldrini2023systematicreviewand pages 9-12) Highlights real-world psychosocial treatment formats (group, family, individual, school-linked combined approaches) for adolescent disruptive behavior disorders, including ODD (boldrini2023systematicreviewand pages 9-12) Not in text https://doi.org/10.1016/j.jaac.2022.05.002 May 2023
Halldorsdottir, 2023 Clinical cohort / treatment-outcome stratification 134 treatment-seeking youths with ODD (mean age 9.67 years; 36.6% female) Four profiles identified by anxiety and conduct symptoms; >30% of youths with ODD also meet CD criteria and up to 60% meet anxiety disorder criteria in cited clinical literature; Moderate Anxiety/High Conduct Problems subgroup had more severe behavior, worse emotional self-control/executive functioning, and worse long-term psychosocial treatment outcomes (halldorsdottir2023cooccurringconductproblems pages 1-2) Supports heterogeneity model of ODD in which co-occurring anxiety and conduct problems mark distinct mechanisms and prognosis (negative emotionality, executive dysfunction) (halldorsdottir2023cooccurringconductproblems pages 1-2) Not in text https://doi.org/10.3390/ijerph20043405 Feb 2023
Aebi, 2016 GWAS / candidate-gene study Children/adolescents with ADHD assessed for ODD dimensions/subtypes ODD heritability estimated around 0.60 in background; no hypothesis-driven association for DRD4, 5-HTTLPR, or OXTR variants; no genome-wide significant loci; inadequate parenting significantly associated with all ODD dimensions, especially defiant/vindictive behavior (aebi2016gene‐setandmultivariate pages 1-2) Top-ranked genes converged in a protein interaction network centered on beta-catenin signaling and neurite outgrowth, suggesting neurodevelopmental pathway involvement (aebi2016gene‐setandmultivariate pages 1-2) Not in text https://doi.org/10.1002/ajmg.b.32346 Jul 2016
Barker, 2018 Epigenetics / methylome-wide association 671 mother–child pairs from epidemiological birth cohort; DNA methylation at birth linked to ODD trajectories ages 7–13 Methylome-wide significant associations found for ODD and headstrong trajectories, not irritable; ODD worldwide lifetime prevalence quoted as 10%; majority of ODD cases have at least one concurrent psychiatric diagnosis (barker2018amethylomewideassociation pages 1-2) Biological overlap between ODD/headstrong and ADHD; DNA methylation partly genetically influenced; prenatal maternal anxiety associated with headstrong methylation signatures and cigarette smoking with ODD/headstrong signals (barker2018amethylomewideassociation pages 1-2) Not in text https://doi.org/10.1111/cdev.12957 Sep 2018
Demontis, 2021 GWAS ADHD + disruptive behavior disorders (including ODD/CD): 3,802 cases, 31,305 controls, plus Chinese replication Identified 3 genome-wide significant loci for ADHD+DBDs; chromosome 11 locus rs7118422 replicated across ancestries (P=3.15×10^-10, OR=1.17); SNP-heritability 0.34 for ADHD+DBDs vs 0.20 for ADHD alone; strong genetic correlations with aggression (rg=0.81) and antisocial behavior (rg=0.82) (aebi2016gene‐setandmultivariate pages 1-2) Indicates ODD/CD comorbidity with ADHD reflects heavier common-variant burden and aggression-related polygenic loading (aebi2016gene‐setandmultivariate pages 1-2) Not in text https://doi.org/10.1038/s41467-020-20443-2 Jan 2021
Deters, 2020 Neuropsychology / case-control Youth aged 8–18 with ODD (n=44), CD (n=48, with/without ODD), and healthy controls (n=86) Visual working memory and inhibitory control impaired in ODD and CD vs controls; anger recognition impaired in ODD; deficits not explained by comorbid ADHD or internalizing symptoms (hawes2023oppositionaldefiantdisorder pages 16-19) Supports distinct neurocognitive deficits in ODD, especially inhibitory control and anger-recognition dysfunction, independent of ADHD comorbidity (hawes2023oppositionaldefiantdisorder pages 16-19) Not in text https://doi.org/10.1080/15622975.2020.1747114 Apr 2020
Thöne, 2023 Symptom-level clinical study 474 German school-age children in ESCAschool ADHD/disruptive behavior cohort (81% male; mean age 8.90 years) ODD symptom “Argues with Adults” contributed 10% of explained variance in global functional impairment related to ODD/CD/CU symptoms; relationships with adults/children and recreational activities were especially linked to disruptive symptoms (hawes2023oppositionaldefiantdisorder pages 6-9) Demonstrates that individual ODD symptoms differ in impact on functioning, useful for symptom-prioritized assessment and intervention planning (hawes2023oppositionaldefiantdisorder pages 6-9) Not in text https://doi.org/10.1007/s10862-023-10025-z Mar 2023
NCT06194994, 2024 Registry / interventional trial Planned 196 Icelandic-speaking children aged 6–12 with ODD Recruiting RCT testing whether emotion regulation moderates response to Parent Management Training vs Tuning Your Temper CBT; outcomes include Disruptive Behaviour Rating Scale and K-SADS-PL diagnostic status pre, post, 6 and 18 months (NCT06194994 chunk 1, NCT06194994 chunk 2) Explicitly tests precision-treatment hypothesis that emotion dysregulation is a mechanistic moderator of ODD treatment response (NCT06194994 chunk 1, NCT06194994 chunk 2) Not in text https://clinicaltrials.gov/study/NCT06194994 Jan 2024
NCT06410495, 2024 Registry / interventional trial Children aged 8–17 with prior ODD diagnosis and insomnia plus parents Recruiting pilot web-based dyadic CBT-I trial (NiteCAPP SINCC); outcomes include daily sleep diary sleep efficiency/onset latency/total sleep time, actigraphy, HRV, and DBD checklist measures (NCT06410495 chunk 1) Connects sleep dysregulation, parenting stress, and oppositional symptoms in a digital family-based implementation model (NCT06410495 chunk 1) Not in text https://clinicaltrials.gov/study/NCT06410495 May 2024
NCT07044609, 2025 Registry / phase IV drug trial Planned children aged 6–12 with ADHD and comorbid ODD Not-yet-recruiting Phase IV randomized placebo-controlled trial of clonidine ER oral suspension; primary outcome ADHD-RS-5 change; secondary outcomes include Conners 4 ODD scale, CGI, sleep, vitals, ECG, labs, suicidality (NCT07044609 chunk 1, NCT07044609 chunk 2) Illustrates ongoing pharmacologic implementation focused on ADHD+ODD comorbidity rather than ODD-only monotherapy (NCT07044609 chunk 1, NCT07044609 chunk 2) Not in text https://clinicaltrials.gov/study/NCT07044609 Jul 2025
NCT00406354, 2006 Registry / phase IV drug trial 181 children/adolescents aged 6–17 with ADHD and comorbid ODD in Germany Completed 3-arm randomized double-blind placebo-controlled atomoxetine trial; primary endpoint SNAP-IV Revised ODD subscale at 9 weeks, with ADHD and family-impact secondary measures (NCT00406354 chunk 1) Represents real-world psychopharmacology for ADHD+ODD comorbidity using ADHD-directed medication and ODD symptom outcomes (NCT00406354 chunk 1) Not in text https://clinicaltrials.gov/study/NCT00406354 Nov 2006

Table: This table summarizes the most important citable sources retrieved in the session on Oppositional Defiant Disorder, spanning reviews, cohorts, RCTs, molecular studies, and active clinical trials. It highlights the strongest recent evidence on epidemiology, mechanisms, and treatment implementation for rapid use in the final report.

Notes on evidence gaps and constraints

  • PMIDs: Not available in the retrieved full-text excerpts for most sources; therefore, PMID fields are reported as “Not in text.”
  • MONDO/MeSH/ICD code strings: Not identified in retrieved texts; report includes classification placement/specifiers but not alphanumeric codes.
  • ODD-specific pharmacotherapy efficacy: Limited in retrieved evidence; pharmacotherapy evidence largely pertains to ADHD with comorbid ODD endpoints.

References

  1. (hawes2023oppositionaldefiantdisorder pages 1-6): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.

  2. (hawes2023oppositionaldefiantdisorder pages 55-59): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.

  3. (hawes2023oppositionaldefiantdisorder pages 16-19): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.

  4. (balia2020…behaviourin pages 26-29): C Balia. … behaviour in children and adolescents with conduct disorder or oppositional defiant disorder: neuropsychological characterization and drug treatments. preliminary …. Unknown journal, 2020.

  5. (hawes2023oppositionaldefiantdisorder pages 19-22): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.

  6. (NCT06410495 chunk 1): Melanie Stearns. Digital Dyadic Family Based Intervention to Improve Sleep in Children with ODD and Their Parents: NiteCAPP SINCC (Pilot). University of South Florida. 2024. ClinicalTrials.gov Identifier: NCT06410495

  7. (NCT06194994 chunk 1): Urdur Njardvik. Emotion Regulation as a Moderator of Two Different Treatments for Children With ODD. University of Iceland. 2024. ClinicalTrials.gov Identifier: NCT06194994

  8. (boldrini2023systematicreviewand pages 9-12): Tommaso Boldrini, Viola Ghiandoni, Elisa Mancinelli, Silvia Salcuni, and Marco Solmi. Systematic review and meta-analysis: psychosocial treatments for disruptive behavior symptoms and disorders in adolescence. Journal of the American Academy of Child and Adolescent Psychiatry, May 2023. URL: https://doi.org/10.1016/j.jaac.2022.05.002, doi:10.1016/j.jaac.2022.05.002. This article has 17 citations and is from a highest quality peer-reviewed journal.

  9. (ezpeleta2019firstincidenceage pages 1-2): Lourdes Ezpeleta, J Blas Navarro, Nuria de la Osa, Eva Penelo, and Josep Maria Domènech. First incidence, age of onset outcomes and risk factors of onset of dsm-5 oppositional defiant disorder: a cohort study of spanish children from ages 3 to 9. BMJ Open, 9:e022493, Mar 2019. URL: https://doi.org/10.1136/bmjopen-2018-022493, doi:10.1136/bmjopen-2018-022493. This article has 29 citations and is from a peer-reviewed journal.

  10. (barker2018amethylomewideassociation pages 1-2): Edward D Barker, Esther Walton, Charlotte A M Cecil, Richard Rowe, Sara R Jaffee, Barbara Maughan, Thomas G O'Connor, Argyris Stringaris, Alan J Meehan, Wendy McArdle, Caroline L Relton, and Tom R Gaunt. A methylome-wide association study of trajectories of oppositional defiant behaviors and biological overlap with attention deficit hyperactivity disorder. Child Development, 89:1839-1855, Sep 2018. URL: https://doi.org/10.1111/cdev.12957, doi:10.1111/cdev.12957. This article has 34 citations and is from a highest quality peer-reviewed journal.

  11. (hawes2023oppositionaldefiantdisorder pages 6-9): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.

  12. (aebi2016gene‐setandmultivariate pages 1-2): Marcel Aebi, Marjolein M. J. van Donkelaar, Geert Poelmans, Jan K. Buitelaar, Edmund J. S. Sonuga‐Barke, Argyris Stringaris, IMAGE consortium, Stephen V. Faraone, Barbara Franke, Hans‐Christoph Steinhausen, and Kimm J. E. van Hulzen. Gene‐set and multivariate genome‐wide association analysis of oppositional defiant behavior subtypes in attention‐deficit/hyperactivity disorder. American Journal of Medical Genetics, 171:573-588, Jul 2016. URL: https://doi.org/10.1002/ajmg.b.32346, doi:10.1002/ajmg.b.32346. This article has 61 citations.

  13. (hawes2023oppositionaldefiantdisorder pages 33-36): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.

  14. (hawes2023oppositionaldefiantdisorder pages 12-16): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.

  15. (ezpeleta2019firstincidenceage pages 6-7): Lourdes Ezpeleta, J Blas Navarro, Nuria de la Osa, Eva Penelo, and Josep Maria Domènech. First incidence, age of onset outcomes and risk factors of onset of dsm-5 oppositional defiant disorder: a cohort study of spanish children from ages 3 to 9. BMJ Open, 9:e022493, Mar 2019. URL: https://doi.org/10.1136/bmjopen-2018-022493, doi:10.1136/bmjopen-2018-022493. This article has 29 citations and is from a peer-reviewed journal.

  16. (halldorsdottir2023cooccurringconductproblems pages 1-2): Thorhildur Halldorsdottir, Maria G Fraire, Deborah A. G. Drabick, and Thomas H. Ollendick. Co-occurring conduct problems and anxiety: implications for the functioning and treatment of youth with oppositional defiant disorder. International Journal of Environmental Research and Public Health, 20:3405, Feb 2023. URL: https://doi.org/10.3390/ijerph20043405, doi:10.3390/ijerph20043405. This article has 11 citations.

  17. (paiva2024parenttrainingfor pages 1-2): Gabrielle Chequer de Castro Paiva, Jonas Jardim de Paula, Danielle de Souza Costa, Antônio Alvim-Soares, Daniel Augusto Ferreira e Santos, Julia Silva Jales, Marco Aurélio Romano-Silva, and Débora Marques de Miranda. Parent training for disruptive behavior symptoms in attention deficit hyperactivity disorder: a randomized clinical trial. Frontiers in Psychology, Feb 2024. URL: https://doi.org/10.3389/fpsyg.2024.1293244, doi:10.3389/fpsyg.2024.1293244. This article has 22 citations and is from a peer-reviewed journal.

  18. (NCT00406354 chunk 1): Comparison of Atomoxetine Versus Placebo in Children and Adolescents With ADHD and Comorbid ODD in Germany. Eli Lilly and Company. 2006. ClinicalTrials.gov Identifier: NCT00406354

  19. (NCT07044609 chunk 1): A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD. Las Vegas Medical Research, LLC DBA Vector Clinical Trials. 2025. ClinicalTrials.gov Identifier: NCT07044609

  20. (NCT07044609 chunk 2): A Study to Assess the Effectiveness and Safety of Clonidine Extended-Release OnydaTM XR in Children With ADHD and ODD. Las Vegas Medical Research, LLC DBA Vector Clinical Trials. 2025. ClinicalTrials.gov Identifier: NCT07044609

  21. (hawes2023oppositionaldefiantdisorder pages 36-39): David J. Hawes, Frances Gardner, Mark R. Dadds, Paul J. Frick, Eva R. Kimonis, Jeffrey D. Burke, and Graeme Fairchild. Oppositional defiant disorder. Nature Reviews Disease Primers, 9:1-17, Jun 2023. URL: https://doi.org/10.1038/s41572-023-00441-6, doi:10.1038/s41572-023-00441-6. This article has 98 citations.

  22. (helander2023parentmanagementtraining pages 5-7): Maria Helander, Pia Enebrink, Clara Hellner, and Johan Ahlen. Parent management training combined with group-cbt compared to parent management training only for oppositional defiant disorder symptoms: 2-year follow-up of a randomized controlled trial. Child Psychiatry and Human Development, 54:1112-1126, Jan 2023. URL: https://doi.org/10.1007/s10578-021-01306-3, doi:10.1007/s10578-021-01306-3. This article has 22 citations and is from a peer-reviewed journal.

  23. (NCT06194994 chunk 2): Urdur Njardvik. Emotion Regulation as a Moderator of Two Different Treatments for Children With ODD. University of Iceland. 2024. ClinicalTrials.gov Identifier: NCT06194994